Refining Value

Home
Archive
About
How wide is the net?
On drug selection for IRA negotiation
New
Top
Community
Waves of reform
On EUnetHTA 21 Joint Clinical Assessment
Challenges in access innovation
On the "Netflix model" for hepatitis C treatments
Shifting tides
On drug pricing and Medicare reform
The forest and the trees
On capping insulin out-of-pocket costs in HR6833
Valuing life in decisionmaking
On US cost thresholds for VSLs and QALYs
The webs of international reference pricing
On HR3 and the shortcomings of reference pricing
Pharma-payer mutual disarmament
On reducing administrative burden by trading lower prices for fewer access barriers
Refining Value
The economics of drug development and innovation

Refining Value

AboutArchive
© 2023 Refining Value
Privacy ∙ Terms ∙ Collection notice
Start WritingGet the app
Substack is the home for great writing